清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Prevalence of Drug Resistance and Genetic Transmission Networks Among Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients with Antiretroviral Therapy Failure in Guangxi, China

逆转录酶 病毒学 抗药性 传输(电信) 医学 亚型 生物 聚合酶链反应 基因 遗传学 计算机科学 电气工程 工程类 程序设计语言
作者
De'e Yu,Bingyu Liang,Yuan Yang,Jie Liu,Huayue Liang,Shirong Wang,Jiaxiao Jiang,Jiegang Huang,Shanmei Zhong,Cai Qin,Junjun Jiang,Hao Liang,Li Ye
出处
期刊:AIDS Research and Human Retroviruses [Mary Ann Liebert, Inc.]
卷期号:38 (10): 822-830
标识
DOI:10.1089/aid.2021.0181
摘要

Prevalence of drug resistance (DR) challenges the epidemic control of human immunodeficiency virus (HIV)-1. However, little is known about DR among patients with antiretroviral therapy (ART) failure in Guangxi province, China. This cross-sectional study was aimed to investigate the prevalence of DR and the characteristics of DR sequences in the genetic transmission network among HIV-1 patients with ART failure in Guangxi. We enrolled 358 eligible patients between 2012 and 2018. Blood samples were subjected to reverse transcription polymerase chain reaction, followed by sequencing of the HIV-1 polymerase (pol) gene. An online subtyping tool and neighbor-joining phylogenetic tree were used to determine the genotype. HIV-TRACE tool was used to constructed transmission network with a pairwise genetic distance of 0.013. DR was analyzed using the Stanford University HIV Drug Resistance Database. We obtained 293 pol-sequences from participants; CRF01_AE (75.4%), CRF 08_BC (15.7%), and CRF07_BC (8.5%) were the main subtypes, and an A1 subtype was detected in Guangxi for the first time. The overall prevalence of DR was 32.4% (95/293). Among those with identified DR, 25.6% were against non-nucleoside analog reverse-transcriptase inhibitors (NNRTIs), 17.7% were against nucleoside analog reverse-transcriptase inhibitors (NRTIs), and 14.3% were against both NRTIs and NNRTIs. The common drug-resistant mutations were M184V (10.2%), K103N (10.6%) and V179D (6.1%). The patients located in the southern Guangxi [adjust odds ratio (AOR) = 10.87], or whose blood plasma were taken in 2017–2018 (AOR = 3.98) had an increased risk of DR. Of the CRF01_AE, CRF07_BC, and CRF08_BC sequences, 18.6%, 8.0%, and 13.0% fell into clusters, respectively. Nine (9.7%) sequences from patients with DR fell into three clusters. The largest cluster containing 11 individuals was the CRF01_AE subtype, 27.3% of whom were DR patients. Although the prevalence of DR among ART failure patients in Guangxi was at a low level, the continuous surveillance of DR in ART patients is necessary.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哈哈哈完成签到,获得积分10
12秒前
luo完成签到,获得积分10
15秒前
chiien完成签到 ,获得积分10
18秒前
标致初曼完成签到,获得积分10
18秒前
54秒前
shaowen发布了新的文献求助10
59秒前
1分钟前
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
懒得起名字完成签到 ,获得积分10
2分钟前
4分钟前
zkwgly发布了新的文献求助10
4分钟前
万能图书馆应助zkwgly采纳,获得10
4分钟前
CCC完成签到,获得积分10
4分钟前
feiyafei完成签到 ,获得积分10
5分钟前
5分钟前
小瓶盖完成签到 ,获得积分10
6分钟前
我是老大应助大钱采纳,获得10
6分钟前
lalala完成签到,获得积分10
6分钟前
枯叶蝶完成签到 ,获得积分10
6分钟前
mokucyan发布了新的文献求助10
7分钟前
zm完成签到 ,获得积分10
8分钟前
mokucyan完成签到,获得积分10
8分钟前
9分钟前
9分钟前
缓慢冬莲发布了新的文献求助10
9分钟前
六一儿童节完成签到 ,获得积分0
9分钟前
9分钟前
9分钟前
Mia关闭了Mia文献求助
9分钟前
大医仁心完成签到 ,获得积分10
10分钟前
两个榴莲完成签到,获得积分0
10分钟前
automan完成签到 ,获得积分10
10分钟前
11分钟前
科研通AI2S应助科研通管家采纳,获得10
11分钟前
zhaojiantgu完成签到 ,获得积分10
12分钟前
12分钟前
魔仙堡狸花猫完成签到 ,获得积分10
12分钟前
缓慢冬莲发布了新的文献求助10
12分钟前
13分钟前
高分求助中
Standards for Molecular Testing for Red Cell, Platelet, and Neutrophil Antigens, 7th edition 1000
HANDBOOK OF CHEMISTRY AND PHYSICS 106th edition 1000
ASPEN Adult Nutrition Support Core Curriculum, Fourth Edition 1000
Signals, Systems, and Signal Processing 610
脑电大模型与情感脑机接口研究--郑伟龙 500
GMP in Practice: Regulatory Expectations for the Pharmaceutical Industry 500
简明药物化学习题答案 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6299595
求助须知:如何正确求助?哪些是违规求助? 8116748
关于积分的说明 16991114
捐赠科研通 5360511
什么是DOI,文献DOI怎么找? 2847612
邀请新用户注册赠送积分活动 1825116
关于科研通互助平台的介绍 1679387